SureTrader Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, lasers, John_Langston, IB_, sitten-bull
Search This Board:
Last Post: 5/4/2016 6:28:03 AM - Followers: 740 - Board type: Free - Posts Today: 17

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/03/2016 11:52:20 AM
ELTP News: Initial Statement of Beneficial Ownership (3) 04/25/2016 12:43:52 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 04/15/2016 03:14:26 PM
ELTP News: Current Report Filing (8-k) 04/12/2016 08:31:16 AM
ELTP News: Statement of Changes in Beneficial Ownership (4) 03/21/2016 05:08:13 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 05/03/2016 11:52:20 AM
#193807  Sticky Note ELITE PHARMACEUTICAL positioned to capitalize on opiod crisis NASDAQ2020 04/11/16 04:41:02 PM
#189575  Sticky Note 4-REASONS-ELTP-is-in-the-Midst-of-the-Perfect-Storm:-A-GREAT-BUY-NOW: Couch 03/18/16 07:41:32 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#182215  Sticky Note With all due respect, everyone keeps talking about Je3232 02/04/16 12:19:02 PM
#180358  Sticky Note Elite delivered every promise they made, sometime bit Dr_Thorfin 01/24/16 09:06:16 AM
#198078   Maybe Elite can give Canada a price they NASDAQ2020 05/04/16 07:46:06 AM
#198077   Such a joke already with everyone ( all Je3232 05/04/16 06:28:03 AM
#198076   Would be interesting to see what kind of Jimmy Joe 05/04/16 06:23:57 AM
#198075   Elite management did not lie about the valuation Je3232 05/04/16 06:18:24 AM
#198074   I think it's safe to say that investors Je3232 05/04/16 06:12:45 AM
#198073   I thought the CC wasn't until June 14 Je3232 05/04/16 06:07:03 AM
#198072   Isn't another fact the price drop of approximately Je3232 05/04/16 06:04:12 AM
#198071   QTR report and CC Tuesday or Wednesday next ARbigguy1 05/04/16 05:30:29 AM
#198070   PR for Elite's quarterly report! ARbigguy1 05/04/16 05:25:46 AM
#198069   Abuse-Deterrent Opioid Bill Breezes Through House Committee KravMD 05/04/16 05:08:26 AM
#198068   Are we going to test the low .20's stockboy 05/04/16 02:19:14 AM
#198067   I strongly suggest new and old investors to Dr_Thorfin 05/04/16 12:57:19 AM
#198066   Yes, it's been received. rollin2nyte 05/04/16 12:52:13 AM
#198065   Quote- the FDA will never approve a Dr_Thorfin 05/04/16 12:45:18 AM
#198064   Do we know whether or not they did Sixman 05/04/16 12:22:53 AM
#198063   Of course thAt is just another opinion unbounded Dr_Thorfin 05/04/16 12:18:29 AM
#198062   Quote- Only God can help turn the tide! Dr_Thorfin 05/04/16 12:14:42 AM
#198061   Only God can help turn the tide! jtf3 05/03/16 11:27:22 PM
#198060   Ye, ELTP's value has changed since then. It's Sixman 05/03/16 11:26:45 PM
#198058   Why did Elite not receive the 5 million IB_ 05/03/16 10:56:48 PM
#198057   the CEO, management and the company would dr_lowenstein 05/03/16 10:37:13 PM
#198056   LOL LOL thanks for more meaningless bloviating links. dr_lowenstein 05/03/16 10:34:03 PM
#198053   2009 called. They want their warrants complaint back. WeeZuhl 05/03/16 09:58:24 PM
#198052   Now, do not be surprised if the name no2koolaid 05/03/16 09:53:44 PM
#198050   The nonsense is in the request...but allow me no2koolaid 05/03/16 09:45:10 PM
#198049   Of course thAt is just another opinion unbounded dr_lowenstein 05/03/16 09:38:14 PM
#198048   Fantasyland Where this misinformation comes from, I don't know. namtae 05/03/16 09:35:39 PM
#198047   There is no big question because investors are no2koolaid 05/03/16 09:20:16 PM
#198046   What is sad is the presupposition that investors no2koolaid 05/03/16 09:17:22 PM
#198045   SequestOx™ can be administered in capsule form, sprinkled NASDAQ2020 05/03/16 09:14:40 PM
#198044   I'm so sorry to disappoint you but I'm newguy11 05/03/16 09:00:15 PM
#198043   Fugazy valuation report lol How on earth do investors namtae 05/03/16 08:41:06 PM
#198042   Nah, that is not how it goes at no2koolaid 05/03/16 08:23:32 PM
#198041   The big question is what are are the John_Langston 05/03/16 08:22:14 PM
#198040   How did that turn out? Focusing on no2koolaid 05/03/16 08:21:00 PM
#198039   Show me the regs that say it was dr_lowenstein 05/03/16 08:19:28 PM
#198038   And yes we do. Miracle of miracles...I no2koolaid 05/03/16 08:16:51 PM
#198037   No actually I do not know but thanks anyway dr_lowenstein 05/03/16 08:15:36 PM
#198036   Yes, but I would have to identify myself no2koolaid 05/03/16 08:12:37 PM
#198035   LOL no of course savvy investors never bought dr_lowenstein 05/03/16 08:10:14 PM
#198034   Same response...LOLOLOLOL no2koolaid 05/03/16 08:10:03 PM
#198033   Investors are now making decisions about investing in no2koolaid 05/03/16 08:08:46 PM
#198032   do you have a link to support that dr_lowenstein 05/03/16 07:56:10 PM
#198031   Valuation going up July 14 !! NASDAQ2020 05/03/16 07:51:46 PM
#198029   about right, somewhere between a dime and 2 pennies dr_lowenstein 05/03/16 07:16:23 PM
#198028   well no since arguing about the old valuation dr_lowenstein 05/03/16 07:12:38 PM
#198027   Not this again...The current valuation for Elite is no2koolaid 05/03/16 06:14:31 PM
#198026   The nearly 3 year old valuation? Don't worry, mrwrn2010 05/03/16 06:00:20 PM
#198024   .20's coming soon to an OTC stock nearest stockboy 05/03/16 05:42:51 PM
#198020   The only thing in my profile regarding Elite richme 05/03/16 04:33:59 PM